• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Atrial Fibrillation Regimens Yield Comparable Short-Term Outcomes in Prospective Study

by
November 10, 2026
in Health
Reading Time: 3 mins read
0
Atrial Fibrillation Regimens Yield Comparable Short-Term Outcomes in Prospective Study

Atrial Fibrillation Regimens Yield Comparable Short-Term Outcomes in Prospective Study

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Short-term clinical outcomes showed non-inferiority between a regimen combining a direct oral anticoagulant with a beta-blocker and a regimen combining a direct oral anticoagulant with a class III antiarrhythmic in patients diagnosed with atrial fibrillation, according to a prospective observational study published in BMC Cardiovascular Disorders.

Atrial fibrillation frequently occurs alongside structural cardiac remodeling as well as multiple concurrent health conditions. To examine these associations, researchers designed the prospective observational investigation to characterize the demographic, echocardiographic, and biological profiles of affected individuals and to evaluate how different therapeutic protocols performed over a short follow-up window.

The study enrolled 81 patients with atrial fibrillation who underwent detailed baseline evaluations, including comprehensive echocardiography alongside biochemical and hormonal analyses. Patients were randomized to two treatment protocols, with investigators tracking time-to-event outcomes at three-month and six-month follow-up visits using Cox proportional hazards regression models with a significance threshold established at a p value of less than 0.05.

The patient cohort had an average age of 64.4 ± 11.0 years, with 51.6 percent of the participants aged 65 years or older. A majority of the enrolled individuals were male, reflecting the demographic distribution within the evaluated clinical cohort.

Echocardiographic measurements demonstrated an average left ventricular ejection fraction of 55.3 percent across the study population. Evidence of structural cardiac remodeling was widespread, marked by left atrial enlargement in 81.1 percent of patients, left ventricular hypertrophy in 53.7 percent, left ventricular dilation in 49.5 percent, right atrial enlargement in 48.4 percent, and right ventricular dilation in 46.3 percent.

Biochemical and clinical testing revealed a notable burden of concurrent systemic conditions among the participants. Heart failure was documented in 46.3 percent of the cohort, predominantly presenting as heart failure with preserved ejection fraction, while hepatocytolysis was detected in 48.4 percent, thyroid disorders were observed in 17.9 percent, and renal impairment affected 15.8 percent of the patients.

Direct comparisons between the two treatment arms revealed largely comparable echocardiographic and biological parameters, although patients assigned to direct oral anticoagulants plus beta-blockers exhibited a significantly higher left atrial volume than those receiving class III antiarrhythmics (p = 0.045). Both therapeutic strategies proved generally well tolerated, with the demonstrated non-inferiority in short-term outcomes supporting the implementation of rate-control approaches in appropriately selected patients.

Published as an open-access research paper on November 3, 2026, the report represents peer-reviewed accepted findings shared ahead of the final Version of Record to facilitate early access to clinical outcome data.

Subject of Research: Short-term clinical outcomes and patient characteristics across atrial fibrillation treatment regimens

Article Title: Clinical, echocardiographic and biological characteristics and short-term outcomes of patients with atrial fibrillation according to treatment regimen: a prospective observational study

Article References: Lubenga, Y. N., Nkodila, A. N., Otshudi, R. K., Masendu, D. M., Tshilanda, M. B., Kabamba, R. K., Kadima, C. N., Zokere, T. B., Pambu, D., Gondele, D. I., Irung, O. I., Kintoki, E. V., Mbutiwi, F. I. N., Buila, N. B., & M’buyamba-Kabangu, J.-R. (2026). Clinical, echocardiographic and biological characteristics and short-term outcomes of patients with atrial fibrillation according to treatment regimen: a prospective observational study. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-026-06963-7

Image Credits: AI Generated

DOI: 10.1186/s12872-026-06963-7

Keywords: atrial fibrillation, cardiac remodeling, direct oral anticoagulants, beta-blockers, class III antiarrhythmics, echocardiography, left ventricular ejection fraction, left atrial enlargement, left ventricular hypertrophy, right ventricular dilation, right atrial enlargement, heart failure with preserved ejection fraction, renal impairment, hepatocytolysis, thyroid disorders, rate control, Cox proportional hazards, prospective observational study

News Source: Ophelia Keating. (November 10, 2026). Atrial Fibrillation Regimens Yield Comparable Short-Term Outcomes in Prospective Study. Scienmag.

Tags: Atrial Fibrillationbeta blockerscardiac remodelingclass III antiarrhythmicsCox proportional hazardsdirect oral anticoagulantsechocardiographyheart failure with preserved ejection fractionhepatocytolysisleft atrial enlargementleft ventricular ejection fractionleft ventricular hypertrophyprospective observational studyrate controlrenal impairmentright atrial enlargementright ventricular dilationthyroid disorders
Share12Tweet7Share2ShareShareShare1

Related Posts

Delphi Consultation Establishes Homogeneous Nursing Protocol for Pediatric Vasovagal Syncope

Delphi Consultation Establishes Homogeneous Nursing Protocol for Pediatric Vasovagal Syncope

November 18, 2026
Dexmedetomidine Matched Nalbuphine Pain Relief with Lighter Sedation in Pediatric ICU

Dexmedetomidine Matched Nalbuphine Pain Relief with Lighter Sedation in Pediatric ICU

November 18, 2026

Automated Resuscitation System Stabilizes Arterial Pressure and Blood Flow in Canine Shock

November 18, 2026

Blast Thoracic Trauma and Hemorrhagic Shock Trigger Remote Intestinal Cellular Stress in Mice

November 18, 2026

POPULAR NEWS

  • Copper Nanoparticles Enhance Corrosion Resistance in Direct-to-Metal Coatings

    Copper Nanoparticles Enhance Corrosion Resistance in Direct-to-Metal Coatings

    29 shares
    Share 12 Tweet 7
  • Electroacupuncture Modulates Hippocampal RNA Fusion Transcripts in Traumatic Brain Injury Rats

    29 shares
    Share 12 Tweet 7
  • Combined Malnutrition and Poor Quality of Life Elevate Digestive Cancer Mortality

    29 shares
    Share 12 Tweet 7
  • Meta-Learning Accelerates Microwave Hyperthermia Antenna Optimization in Proof-of-Concept Study

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

SEC-HIoT Cuts IoT Device Decryption Cost to 2.3 Milliseconds

Delphi Consultation Establishes Homogeneous Nursing Protocol for Pediatric Vasovagal Syncope

Dexmedetomidine Matched Nalbuphine Pain Relief with Lighter Sedation in Pediatric ICU

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.